Creating standards in the field of Biophotonics through innovative phantoms that simulate human tissue optical properties.
96% of translational biophotonics research fail. One of the key reasons is the lack of a standardised approach to assesses the performance of biophotonics devices. Our innovative, commercially unique phantoms simulate the optical properties of tissue and create a standardised approach to assess device performance. This accelerates instrument development at reduced costs in the field of biophotonics.
Few potential areas of application include the use of phantoms for:
On the social front, our phantoms target to reduce the animals used in preclinical trials by providing parallel solutions and optimise clinical trials, thus reducing costs, time for developers and pain experienced by these thousands of animals being exploited in these trials.
Innovative approach:
Our products will reduce the cost and time needed to develop and maintain hi-tech biomedical devices in photonics. It has the potential to revolutionise the entire biophotonics value chain, from laboratory to clinical applications. Our solution directly addresses the key strategic orientation of Horizon Europe Cluster 1 (health) thus positioning us at the centre of the next generation of innovation/emerging markets foreseen in Europe and beyond. The points below are testament to our commercial attractiveness,
We have raised as much as 700000 euros through grants and sales within 4 months of our inception as a company, which is a validation for our value proposition/vision.
VASCOVID/HemoCovid for Covid-19: In these Covid-19 projects, BioPixS phantoms will fast track biophotonics instrument development/deployment at various hospitals to impact recovery of Covid-19 patients. So far, we have shipped our products across the world covering 6 countries. (scope: International)
TinyBrains: BioPixS phantoms will aid the development of neuroimager to understand the origins of CHD (congenital heart disease) in term/preterm infants. (scope: International)
We are looking for exposure and networking opportunities with potential strategic investors and customers for our products.